A recent meta-analysis of randomised controlled trials in patients with HER2+/ER+ breast cancer found that endocrine therapy-containing regimes elicited better efficacy than chemotherapy-containing regimes [34]. This evidence concerns the gene ERBB2 and breast cancer.